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Vulval carcinoma is uncommon, affecting approximately 2 per 100 000  
 
women annually. The treatment of choice is radical vulvectomy and inguinal  
 
lymph node dissection.  
 
 
‘Advanced’ vulval carcinomas involve midline structures (such as clitoris,  
 
urethra or anus) and/or adjacent pelvic organs or bone, and adequate  
 
excision may require urinary diversion, colostomy or pelvic exenteration.  
 
Less morbid and less mutilating therapeutic alternatives have been  
 
investigated, particularly chemoradiation, which has shown significant  
 
success in the management of anal carcinomas.   
 
 
Primary chemoradiation has been used, instead of primary radical surgery, to  
 







1) To assess the survival of women with advanced vulval carcinoma 
 
treated with primary chemoradiation. 
 





















2) To examine the complications and morbidity of chemoradiation. 
 







In this retrospective study, data was transcribed from patient case records  
 





Between 1982 and 2001, 50 women with advanced vulval carcinomas were  
 
treated with chemoradiation at GSH. Fourteen (28%) women who had a  
 
complete response to chemoradiation had significantly improved survival  
 
compared to the 29 (58%) who had a partial response (p = 0.000218). Partial  
 
responders who had surgery had significantly better survival than those who  
 
did not (p = 0.0064). Other prognostic factors for survival were performance  
 
















complete response. Survival was improved in women who responded  
 
partially but had residual disease surgically excised. Performance status, age  
 














































4.  INTRODUCTION 
 








. It is predominantly a disease of older women, with a peak  
 
incidence in the seventh decade; though with the increased incidence of  
 
Human Papilloma Virus (HPV)-related Vulval Intra-epithelial Neoplasia  
 
(VIN usual type) that has accompanied the HIV pandemic, a second peak  
 
incidence in younger women in their forties has developed. 
 
 
Vulval cancer is difficult to treat, both due to the physical, psychological and  
 
sexual morbidity of the radical surgery which may be necessary in order to  
 
gain improved local control and cure rates, and because of the likelihood of  
 
co-morbid disease in older patients. 
 
 
The treatment of choice for vulval carcinoma is modified radical vulvectomy  
 
and inguinal lymph node dissection. This was described by Taussig
3










the mortality rate dropped from over 80% to  
 
40%, though at the expense of high operative mortality and morbidity
5
. The  
 
overall uncorrected 5-year survival rate following this procedure is currently  
 
quoted as 65% (range 46 – 75%)
1












whose inguinal lymph nodes are not yet involved with tumour.  
 
 
The most common complication of this radical surgery is wound breakdown  
 
(85% of patients), with 30 – 70% of women experiencing chronic  
 




. The original radical vulvectomy and en bloc bilateral inguinal  
 
groin node dissections through ‘butterfly’ incisions has been modified over  
 
the years to less extensive vulval surgery, separate groin incisions with  
 
preservation of the skin bridge, and less radical groin node surgery, in order  
 
to decrease morbidity. 
 
 
Thomas et al state that “the role of radiation therapy in the management of  
 
vulvar cancer has not been explored in a systematic fashion”
1
, and reports of  
 
poor survival rates and severe complications, such as skin necrosis, caused  
 
this modality to fall into disrepute. However, several reports of pre-operative  
 
irradiation being used to debulk lesions that would have otherwise have  
 
required pelvic exenteration, suggested that radiotherapy could be used to  
 
reduce the extent of subsequent surgery or even eradicate disease in some  
 
patients if a high enough dose of radiation was used
6,7,8
. This was despite  
 
concerns of increasing the incidence of complications such as fistula  
 












radiotherapy were used.  
 
 
Advanced vulval cancers include both those tumours which involve the  
 
urethra, bladder, anus, rectum or pelvic bone; and those for which adequate  
 
surgical excision requires sacrifice of one of the central structures (clitoris,  
 
urethra and anal sphincter) or even a total pelvic exenterative procedure.  
 
 
Alternative forms of therapy have been sought to alleviate the morbidity of  
 
this radical surgery, and it was observed that concomitant radiotherapy and  
 
chemotherapy with 5-fluorouracil (5FU), resulted in long-term local control  
 
and cure of anal carcinomas, and rapid regression of squamous carcinomas  
 
of the oesophagus, head, neck and cervix
5
. This lead to investigation of the  
 
use of chemoradiation as the primary therapy of vulval carcinoma,  
 
particularly in the radical treatment of advanced tumours.  
 
 
The Groote Schuur Hospital (GSH) Departments of Gynaecological  
 
Oncology and Radiation Oncology have been using chemoradiation in the  
 
management of advanced vulval carcinoma since 1982. This thesis aims to  
 
examine the role of chemoradiation in the management of advanced vulval  
 
carcinoma, with reference to both the outcomes of patients treated at Groote  
 
Schuur Hospital, and a critical review of the literature. It is based on a  
 











carcinoma who were treated with primary chemoradiation at Groote Schuur  
 
Hospital (GSH) between January 1982 and January 2001. 
 
 
Aims of the study: 
 
1) To assess the survival of women with advanced vulval carcinoma  
 
treated with primary chemoradiation. 
 





Objectives of the study: 
 




2) To examine the complications and morbidity of chemoradiation. 
 
3) To determine prognostic factors for survival in women with advanced  
 
























5. REVIEW OF THE LITERATURE 
 
Radical vulvectomy and inguinal lymphadenectomy is the accepted 
treatment for vulval carcinoma; however, for those patients with irresectable 
tumours, a variety of other treatments have been attempted. 
 
 




 and Hacker et al
7
 first suggested the use of pre-operative  
 
radiotherapy to shrink irresectable vulval tumours, in order to reduce the  
 
extent of the surgery required (as an alternative to exenteration).  
 
 
5.2 Radiotherapy combined with chemotherapy 
 
Iversen first attempted to render tumours operable by using radiotherapy  
 
combined with chemotherapy (bleomycin), though conceded that in most  
 






5.3  The Nigro regime for squamous carcinomas of the anal canal 
The use of preoperative chemotherapy (5FU and mitomycin-C) and 
radiotherapy in the treatment of squamous carcinomas of the anal canal was 
begun by Nigro’s group in 1972
10
. Evidence suggested that 5-fluorouracil 











acted as a radiation sensitizer, thereby enhancing cell kill
11
. By 1975 it had 
become apparent that chemoradiation was so effective, producing local 






5.4  Chemoradiation for vulval carcinomas 
 
In a series of 54 women with locally advanced primary and recurrent vulval 
cancers, Han et al showed that overall survival was significantly better in 
patients treated with chemoradiation than with radiotherapy alone (p = 0.04). 
There was also a statistically significant improvement in disease-specific  




In a review of Concomitant 5-Fluorouracil, Mitomycin-C, and Radiotherapy 
for Advanced Gynecologic Malignancies in 1988, Evans et al stated that 
“The treatment of vulval cancers has recently changed from a surgical 
approach to a combined approach using radiotherapy for advanced stages.” 
They concluded that the combination of chemotherapy and radiotherapy 
seemed “tolerable and promising”, though admitted that patient numbers 
















radiation and concurrent 5FU, with or without mitomycin-C, in 33 patients  
 




Of the 33, only 9 patients received primary chemoradiation, and of these 6  
 
had initial complete responses. Three subsequently developed vulval  
 
relapses. Seven of the 9 were disease free after chemoradiation alone, or  
 
with the addition of a local excision of residual or recurrent disease, at the  
 
time of reporting (median duration of follow-up was 16 months).  
 
 
It is notable that doses of radiation to the vulva ranged from 44 to 60 Gy;  
 
and Thomas et al state that patients should be treated with doses of at least  
 
55 Gy in order to increase local control rates. Regarding complications, they  
 
state it is important to keep the daily radiation fraction size to the vulva at  
 
175 cGy or less, in order to minimize the development of vulval fibrosis,  
 
necrosis and atrophy. They found that the moist desquamation which all  
 







Berek et al conducted a phase II trial of concurrent cisplatin and 5FU  
 
chemotherapy and radiotherapy for the primary treatment of 12 patients with  
 
stage 3 and 4 vulval cancer. Complete tumour responses were seen in 8 of 12     
 












disease. Radical vulvectomy or excision was then performed in 3 patients,  
 
and exenteration in one patient. With a median follow-up of 37 months, 10  
 
patients were alive and disease-free, and two patients died at 12 and 15  
 
months respectively. There were no treatment-related deaths, and no Grade 4  
 
toxicity. They stated that their data supports the use of chemoradiation as an  
 
alternative treatment strategy to primary radical surgery in women with  
 





Russell et al reported the use of chemoradiation in the treatment of 25  
 
women with locally advanced or recurrent vulval cancer. Of the 18  
 
previously untreated patients, the majority of whom were stage 3 or 4a, a  
 
complete clinical response was obtained in 16 (89%). They concluded that  
 
initial management with chemoradiation may offer some patients with  
 
locally advanced vulval cancer an alternative to exenterative surgery, and  
 







Koh et al reported the use of chemoradiation in 20 women with locally  
 
advanced vulval cancer. They concluded that there was a suggestion that  
 
better local control was obtained in patients who received radiation doses  
 














Wahlen et al reviewed the outcomes of 19 women treated with combination  
 
therapy in order to evaluate the role of combined chemotherapy and  
 
radiotherapy, with or without local excision, as primary therapy for  
 
advanced vulval cancer. Fifteen patients had stage 3 disease, and four had  
 
stage 2 disease. Two patients with positive ipsilateral inguinal nodes had  
 
these nodes removed before treatment. Median follow-up was 34 months:  
 
complete responses were seen in 10 patients (53%), partial responses in 7  
 
(37%), no response in one woman, and one woman progressed during  
 
treatment. Chemoradiation resulted in a local control rate of 74% (14/19).  
 
All five treatment failures occurred within 6 months of treatment, and four  
 





Cunningham et al treated 14 patients with stage 3 and 4 vulval carcinomas  
 
with chemoradiation, and achieved a 92% response rate. Nine patients (64%)    
 
had complete responses. With a mean follow-up of 36.5 months, only one of  
 
these patients recurred, though all the patients who had partial responses  
 
died, with a mean survival of 15.7 months. Surgical excision of the primary  
 
site was not performed in those who had a complete response, and they  
 

















Lupi et al published a pilot study of the use of preoperative chemoradiation  
 
in locally advanced vulval carcinoma: 31 patients were treated, with a  
 
staggering 65% post-operative morbidity rate, and a mortality rate of 13,8%.  
 
They concluded, unsurprisingly, that the combined approach might offer  
 
new perspectives for the treatment of advanced vulval cancer, if treatment- 
 





Gerszten et al reported the use of twice daily radiation, delivered  
 
concurrently with chemotherapy, to treat advanced and “critically located”  
 
vulval carcinomas. Inguinal nodes were included in the treatment field even  
 
if they were clinically negative. Resection of the tumour bed and inguinal  
 
dissection were planned for 4-6 weeks post-treatment. A retrospective  
 
review of the outcomes of eighteen patients showed there were complete  
 
responses in 13 patients, of whom 12 had no evidence of disease at 25  
 








5.5  The Cochrane Database Systematic Review 
 
A recent Cochrane Database systematic review
 
of neoadjuvant  
 
chemoradiation for advanced primary vulval cancer concluded that patients  
 











chemoradiation if an operation can subsequently be performed, but that the  
 
complications of neoadjuvant therapy might outweigh the complications of  
 
exenterative surgery. They state that “with the current knowledge  
 
neoadjuvant therapy is not justified in patients with tumours that can be  
 







This Cochrane review found that no randomized controlled trials were  
 
available, and only five studies met their inclusion criteria (“Studies of  
 
curative treatment of patients with advanced, primary squamous cell  
 
carcinoma of the vulva… Treatment included concurrent radiotherapy and  
 















Chemotherapy was gi en fairly uniformly in these studies, with three studies  
 
using concomitant cisplatin and 5FU, one using 5FU and mitomycin-C, and  
 
one using bleomycin (this study achieved a significantly lower operability  
 
rate of only 20%). Chemoradiation schedules varied between the studies, as  
 
did the radiotherapy dose fractionation techniques, fields and target  
 
definitions. Skin complications were observed in most of the patients; other  
 












lymphoedema and lymphocysts. Sixty-three – 92% of tumours were   
 
rendered operable in the four studies that utilized 5FU and cisplatin or  
 
mitomycin-C. Periods of follow-up ranged from between 5 and 125 months,  
 
and 26 – 63% of patients were found to be alive and well. Twenty-seven –  
 






5.6  Historic progression 
 
The rationale behind these studies and the historic progression is easy to  
 
follow: the search for alternative treatments to radical surgery, and  
 
particularly exenteration, for inoperable vulval tumours, lead to investigation  
 
of the role of neoadjuvant radiotherapy, and then chemoradiation, with the  
 
use of certain chemotherapies as radiosensitisers. The success of the Nigro  
 
regime to treat squamous carcinoma of the anus was used as an example. 
 
 
The high doses of RT required, and resulting morbidity, have lead to  
 
chemoradiation for advanced vulval cancer falling into disfavour recently, 
 
despite its effectiveness. Elderly women with co-morbid diseases cope  
 
poorly with chemoradiation; and increasingly, younger women are  
 
presenting with multifocal VIN and vulval carcinomas, and their physical,  
 













Advanced vulval cancer is a rare condition, so numbers of patients in the  
 
studies mentioned above are small, and the studies themselves are 
 
inhomogenous. No randomized controlled trials are available, and these are   
 
unlikely to be performed. 
  
 
It is clear that while neoadjuvant chemoradiation can reduce tumour size and  
 
improve operability, the results of respective studies vary considerably, and  
 
no quality of life measurements were available.  
 
 
Future studies should perhaps focus on the role of neoadjuvant  
 
chemotherapy for advanced vulval cancer, in order to further establish its  
 




5.7  Neoadjuvant chemotherapy for advanced vulval cancer 
 
In 1993, Benedetti-Panici et al reported the results of a pilot study using  
 
cisplatin, bleomycin and methotrexate to treat 21 patients with FIGO stage  
 
4a vulval carcinomas, prior to surgery. They achieved local control in 12  
 




















nitrosurea CCNU in 25 patients with locally advanced primary and recurrent  
 
vulval carcinomas. Some of the patients went on to have radical surgery  
 
followed by radiotherapy. There was significant haematological toxicity,  
 
with two treatment-related deaths. The overall response rate was 56%, with a  
 





Between 1997 and 2003, Geisler at al treated fourteen patients with  
 
advanced vulval cancer involving the anal sphincter and/or urethra, with 3-4  
 
cycles of neoadjuvant chemotherapy (cisplatin and 5FU), in order to try to  
 
avoid primary pelvic exenteration. They planned to perform radical  
 
vulvectomy and groin lymph node dissection after 3 cycles of chemotherapy.  
 







The median age of their patients was 63 years (range 39-88). Thirteen  
 
patients received a median of 3 cycles (range 2-4): ten received cisplatin and  
 
5FU, while three received cisplatin alone. Median time from diagnosis to  
 
surgery was 77 days (range 54-143). All except one of the patients who  
 
received cisplatin and 5FU went on to have surgery (they all demonstrated at  
 
least a partial response), while the patients receiving cisplatin alone had no  
 

















All of the patients who received cisplatin and 5FU were disease-free at the  
 
time this paper was written in 2005, while two of the three who received  
 





From these studies, there appears to be a range of responsiveness to the  
 
various chemotherapy combinations, though haematological toxicity remains  
 
a serious concern with all of them. There is as yet no evidence to show the  
 
efficacy or otherwise of substituting a potentially less toxic drug, such as  
 




5.8  EGFR Inhibitors 
 
There is, however, a case report in the recent literature describing the first  
 
experience of the use of Erlotinib (Tarceva) in two elderly patients with  
 
locally advanced vulval cancer
31
. Erlotinib is an oral epidermal growth  
 
factor receptor (EGFR) tyrosine kinase inhibitor, and evidence exists to  
 
show that primary and metastatic vulval cancers have increased expression  
 





These patients were not offered surgery due to having multiple co- 
 











progression on standard chemotherapy with 5FU and cisplatin. Within two  
 
weeks of starting treatment with Erlotinib, one patient had complete  
 
resolution of her 9.9cm vulval tumour and its necrotic lymph node  
 
metastases, and the other had a 50% reduction in size of her 5cm tumour.  
 







Erlotinib is well-tolerated, with diarrhoea, rash and fatigue as its major side- 
 
effects. Due to the biological plausibility of using an EGFR inhibitor to treat  
 
vulval cancer, and the responses seen in this case report, the authors have  
 
initiated a phase II trial to explore the role of Erlotinib in the treatment of  
 





Thus other treatments (such as EGFR inhibitors) besides the traditional  
 
combinations of radical surgery, chemotherapy and radiotherapy, may  
 
become the cornerstones of the treatment of locally advanced vulval cancer  
 




















6.  METHODS 
 
At Groote Schuur Hospital, all women with a diagnosis of a gynaecological  
 
malignancy are referred to a Combined Assessment Clinic (CAC), where  
 
they are seen, assessed and counselled by a team consisting of both  
 
gynaecological oncologists and clinical oncologists. Once they are registered  
 
as a cancer patient with a radiotherapy (RT) folder number, they become  
 
part of a database which is divided into vulval, cervical, endometrial,  
 
ovarian and gestational trophoblastic neoplasia patients. 
 
 
The database provided a list of all women treated with primary  
 
chemoradiation for advanced vulval cancer. These files were retrieved and a  
 





Demographic data, details of the tumour (size, position, involvement of  
 
adjacent structures), details of treatment and follow-up information was  
 
transcribed from the case notes onto the proformas. Standard therapy  
 
consisted of a split course of concomitant chemotherapy and radiotherapy. 
 
 
Chemotherapy consisted of mitomycin-C (10mg/m
2
) given as a bolus  
 
injection on day one of each of the radiotherapy courses. 5-Fluorouracil  
 
(5FU), at a dose of 1000mg/m
2











over 24 hours on days 1 to 4 inclusive. The infusion was begun 30 minutes  
 
after the bolus of mitomycin-C had been injected.  
 
 
Radiotherapy was given via a pair of antero-posterior parallel opposed  
 
portals to include the whole pelvis, vulva and inguinal lymph nodes. Patients  
 
were treated with 10 fractions of 2,5 Gy mid-plane dose to complete the first  
 
course, and then allowed to rest for two weeks to allow the resultant wet  
 
desquamation of the vulva to settle. Fractions were given on five days of the  
 
week using a telecobalt machine.  
 
 
The second course of radiotherapy comprised 10 fractions of 2 Gy to make  
 
up a total of 45 Gy. Regression of the tumour was assessed after the first  
 
course to decide whether the patient required a second course of  
 
chemoradiation, or surgery. 
 
 
The data was computerised and analysed as follows: descriptive statistics  
 
were generated and survival analyses, including generation of Kaplan-Meier  
 
curves, logrank tests and calculation of hazard ratios, were performed using  
 



















Between January 1982 and January 2001, 50 women with advanced vulval  
 
carcinoma were treated with concomitant chemotherapy and radiotherapy at  
 




7.1  Patient Profile 
 
Patients ranged in age from 30 to 82 years, with a median age of 56.5 years.  
 
Parity ranged from 0 to 13, with a median of 3. Patients were drawn from a  
 
wide geographical area: 26 were from out of Cape Town and 11 from the  
 
Eastern Cape. Thirty-one of the women were of mixed race or coloured, 16  
 
women were black, and three women were white. Their WHO performance  
 




Table 1: WHO performance status 
 
WHO performance status Number of patients 
 
No symptoms = 0 
 
38 
Symptomatic but not bedridden = 1 
 
11 
















7.2  Disease Profile 
 
The commonest associated vulval condition was vulval intraepithelial  
 
neoplasia (VIN) in 14 (28%) patients. Five (10%) patients had vulval warts,  
 
and one suffered from lichen sclerosus. 
 
 





































All of the tumours were squamous cell carcinomas, and the majority were 
staged as FIGO stage 3 (60%) or 4a (32%).  Two were stage 4b and two 
were stage 2. Inguinal lymph nodes were unilaterally involved in 9 patients 
(18%) and bilaterally involved in 16 patients (32%), as determined by fine 
needle aspiration or clinical palpation (Table 4).  
 
Twenty-nine of the tumours were considered irresectable without loss of  
 
either urethra, anus or both, or because they were fixed to the pelvic bone.  
 
All of the tumours were larger than 3.1cm in diameter, with the mean  
 
tumour diameter being 8.4cm (Table 2). The vast majority (n = 41 or 82%)     
 
of the tumours were centralized, with 23 situated posteriorly, and 18  
 
anteriorly. Table 3 shows the anatomical sites to which the tumours  
 
extended, and Table 4 shows the status of the groin lymph nodes as  
 
determined by fine needle aspiration (n = 20) or clinical palpation (n = 5).  
 
Nodes were considered ‘negative’ in 25 cases when no nodes were palpated  
 
in the inguinal regions. 
 
 




3.1-4 4.1-5 5.1-6 6.1-7 7.1-8 8.1-9 9.1-10 >10 
Number 
 













Table 3: Sites of extension of disease 
 
Site of extension 
 













Vagina and urethra 
 
8 
Vagina and anus 
 
4 
Vagina and rectum 
 
1 
Vagina and bone 
 
1 
Anus and urethra 
 
1 
Anus, vagina and urethra 
 
2 































Number of patients 
Bilateral fine needle aspiration 
biopsy (FNAB) + 
 
14 
Unilateral FNAB + 
 
6 
Bilateral, not FNAB 
 
2 
























7.3  Association with other cancers 
 
Three women had previously undergone treatment for cervical carcinomas:  
 
of these, one had a hysterectomy for a microinvasive cervical cancer 9 years  
 
before developing a vulval carcinoma, and one had received radiotherapy for  
 
a stage 2b cervical cancer 29 years earlier. Another woman had had an  
 
endometrial carcinoma 16 years before developing a vulval cancer. 
 
 
At the time their vulval cancers were diagnosed, two women were also  
 
found to have early cervical carcinomas (stage 1a and stage 1b2), and  
 
another woman was found to have a laryngeal cancer. Subsequent to  
 
receiving treatment for her vulval cancer, one further woman developed both  
 
a T1N0 breast carcinoma, and a lung cancer, and subsequently died from the  
 



























7.4  Association with immunosuppression 
  
At the time most of these patients were treated, it was not yet our policy, as  
 
it is currently, to test all women undergoing treatment for a gynaecological  
 
malignancies for the human immunodeficiency virus (HIV) after  
 
appropriate counselling. HIV testing has become routine due to the high  
 




, and the influence of a positive test and a low CD4  
 
count on patients’ ability to withstand treatment with chemotherapy and     
 
radiotherapy. Only 14 of the women treated with chemoradiation for  
 
advanced vulval cancers were confirmed to be HIV negative, and one was  
 
suffering from severe malnutrition at the time of presentation. The other 35  
 




























7.5  Treatment 
 
Details of the chemotherapy and radiation regimen used are given under  
 
Methods. There were many variations on the planned treatment regimen,  
 
with 18 patients receiving only one course of treatment. Some patients had  
 
their treatment completed at other centres, such as in the Eastern Cape, and  
 
received differing doses of radiotherapy. Three received additional radiation  
 
boosts to the perineum or inguinal lymph nodes. Deviations from the  
 
planned chemotherapy regimen were fewer: one patient received one cycle  
 
of cisplatin and bleomycin prior to one cycle of 5FU and mitomycin-C; and  
 





Ultimately 33 patients (70%) completed the chemoradiation treatment  
 
regimen planned for them. Six women died during the course of their  
 
treatment (of which three deaths were treatment-related); five had their  
 
treatment discontinued or interrupted due to complications of therapy  
 
(combinations of haematological, GIT and skin complications); and four  
 

















7.5.1 Surgery (Table 5) 
 
Two patients had bilateral groin node dissections (BGND) prior to receiving  
 
chemoradiation: all nodes were negative. Two patients required  
 
defunctioning colostomies after chemoradiation, and a further thirteen  
 
patients had vulval and/ or groin surgery after chemoradiation. One woman  
 
had vulval biopsies only, which showed no residual disease; five had local  
 
excisions only, and one had a local excision and unilateral groi   
 
lymphadenectomy. Four women underwent ‘simple vulvectomies’, and one  
 
had a ‘simple vulvectomy’ and BGND. Only one woman underwent a  
 
































Table 5: Surgery performed post-chemoradiation 
 














Inguinal node dissection only 
 
2 
Bilateral inguinal node dissection 
 
4 



































7.6  Outcomes 
 
There was a complete response (CR), defined as no clinical evidence of  
 
disease after the completion of treatment, following chemoradiation in 14  
 
patients (28%). Ten patients who showed a complete response received two  
 
full courses of treatment. Four patients only received one complete course.  
 
 
A partial response (PR), defined as some degree of tumour regression but  
 
active disease still present after completion of treatment, was recorded in 29  
 
patients (58%).  
 
 
In 7 patients there was no change (NC) despite treatment, though no patients  
 
developed progressive disease while on treatment (Table 6). 
 
 
Table 6: Response to treatment 
 

































Complete responders  
(n = 14)  
Partial responders 
(n = 29)  
Median age 
 




From: Cape Town 
           Eastern Cape 
           Rural Cape 









Ethnic group: Coloured 
                       Black 









0 = 12  
1 = 2 
2 = 0 
0 = 21 
1 = 6 
2 = 1 
Associated vulval 
condition 
VIN = 4    
warts = 1 
VIN = 8 
Warts = 4 
Lichen Sclerosus = 1 
FIGO stage 
 
3 = 12 
4a = 2 
2 = 2 
3 = 15 




7cm 7.1 – 8cm 
Groin lymph node 
status 
 
Clinically negative = 7 
Unilaterally positive = 4 
Bilaterally positive = 3 
 
Clinically negative = 15 
Unilaterally positive = 4 
Bilaterally positive = 9 
 
 
Table 7 shows a comparison between women who had a complete response  
 
to treatment, and those who had a partial response. Of patients who showed  
 












have been lost to follow-up, and 6 were alive with no evidence of disease at   
 
36 months. One patient developed a local recurrence and lung metastases 23  
 
months after treatment and died four months later. Figure 4 shows a Kaplan- 
 









T he hazard ratio between the P R  and C R  groups is 4.97 (95%  
confidence interval 1.97 to 12.6, p-value of logrank test is  0.000218) 
which indicates that there is a significant difference in surviv al between 
the two groups.









































The group that showed a partial response to treatment can be divided into  
 
two subgroups: those who underwent surgery after chemoradiation and those  
 
who did not. Seven patients who showed a partial response underwent vulval 
 
surgery. One of these women died of disease at 41 months. Two were lost to  
 
follow-up at 5 and 9 months with evidence of active disease. The other four  
 
women have all died of unrelated causes. One woman was offered surgery, 
but declined; and a further two women underwent defunctioning 
colostomies. 
 
Eighteen patients who had a partial response to treatment were not offered  
 
surgery. Three of those patients were lost to follow-up. All the others have  
 
died, with an average survival time of 7,8 months. The longest survivor from  
 
this group lived for 34 months, and the next longest lived for only 15  
 
months. Patients who had progressive disease despite treatment survived for  
 
an average of only five months. Figure 5 shows the difference in survival  
 
between those patients with a partial response who underwent surgery, and  
 



















Figure 5: A significant difference in survival between partial responders who  
 
had surgery, and those who did not 
 
T he hazard ratio between the S urgery and No surgery groups is  0 .2 
(95%  confidence interval 0.0567 to 0.708, p-value of logrank test is  
0.0064), which indicates that there is a significant difference in survival 
between the two groups.


























































7.6.1  Complications of Treatment 
 
Three patients died from complications of their treatment. One died from  
 
pancytopaenia, presumably caused by chemotherapy; one died during  
 
therapy of unknown causes (no postmortem was done); and one woman was  
 
severely malnourished prior to commencing treatment, and died during  
 




Table 8: Treatment complications 
Complications Number of patients 
Skin (wet desquamation) 11 
Haematologic 2 
Haematologic and Skin 2 
Haematologic and GIT 1 
Skin and GIT 1 














The mean follow-up period was 37.14 months (range 0 – 179 months). 
Twenty-two of the women developed recurrences during this time, and the 
sites of first recurrence are shown in table 9. 
 
Table 9: Sites of first recurrence 
 
Site of recurrence 
 







Local and groin 
 
8 
Local and distant 
 
1 
































Table 10 shows the follow-up status of the patients, and Figure 6 shows  
 
survival curves for the whole group : 
 
 
Table 10: Current follow-up status of patients 
 
Status Number of patients 
Dead of disease 22 
Dead due to treatment 3 
Dead due to other causes 11 
Alive and clear of disease   6 
Alive with disease 0 





























Figure 6: Survival curves for the whole group 
 






























Fifteen women were known to be alive and free of disease five years after  
 
treatment, giving a disease-free and overall survival rate of 30% at five years  
 
for the whole group. Seven of these women have subsequently died of  
 
unrelated causes (three of these were partial responders who underwent  
 
adjuvant surgery), one died of cancer at 123 months, and one was lost to  
 

















It is notable that of the six surviving women, all demonstrated a complete  
 
response to chemoradiation, all had a good performance status (WHO = 0),  
 
and four of them were aged less than 60 years. Five of the six presented with  
 
stage 3 disease, while one had stage 4a disease. Four of the six had clinically  
 
negative nodes. Five of six completed their treatment, with one not  
 
completing her treatment course due to haematologic and gastrointestinal  
 
complications. The only surgery that this group of women underwent after  
 
chemoradiation was biopsies or local excisions, all of which proved them to  
 
be free of disease. Figure 7 illustrates that women with a better WHO  
 




































There is a significant difference in survival among the patients of three WHO 
performance status (p-value of logrank test is 0.011).






















































Surprisingly, there was not a significant difference in survival between  
 
women with positive groin nodes, and those with negative groin nodes, as  
 
shown in Figure 8. 
 
 
Figure 8: No significant difference in survival between women with positive  
 
groin nodes and those with negative groin nodes 
 
There is no significant difference in survival between the node positive and 
negative patients (p-value of logrank test is 0.213).




























The lack of significant difference in survival could be accounted for by the  
 
fact that only 6 women underwent groin node dissections, and 20 were  
 
proven to have involved groin nodes by fine needle aspiration biopsy.  
 











clinically, so groin node micrometastases could have been missed in this  
 
group, which potentially would have affected their survival.    
 
 
There was, however, a significant difference in survival between patients  
 
with stage 2 or 3, and stage 4a or 4b disease, with those patients with stage  
 









There is a significant difference in survival between the patients  of stage 2 or 
3 and those of stage 4A or 4B (p-value of logrank test is 0.00349).
























Stage 2 or 3














It is therefore clear that those patients who had a complete response to  
 
chemoradiation had the best outcomes, while partial responders who had  
 
surgery did better than partial responders who did not have surgery. Other  
 
predictors of survival were good WHO performance status and earlier stage  
 
of disease. It was surprising that there was not a significant difference in  
 
survival between patients with positive groin nodes and those whose groin  
 
nodes were negative; though as chemoradiation was the primary form of  
 
therapy, this may have been because this was an effective way of sterilizing  
 


































8. DISCUSSION  
 
The Groote Schuur Hospital series is one of the largest series of patients  
 
treated with primary chemoradiation for advanced vulval carcinoma. Our 
 
patient characteristics are markedly different from those of patients in the  
 
developed world, who are likely to be predominantly elderly women with  
 




8.1  Reasons for late presentation 
 
However one similarity all women with vulval lesions share is a tendency to  
 
present late – though the reasons for this may differ, depending on the age of  
 
the patient and their education and socio-economic status. Younger women  
 
tend to present earlier due to vulval symptoms, while in more elderly women  
 
there is often a delay both in presentation and in referral. Patient  
 
embarrassment, and deficiencies in education of both patients and medical  
 
professionals accounts for some of these delays. In developing countries,  
 
lack of easy access to medical care probably is the main factor leading to the  
 


















8.2  Survival 
 
One of the aims of our study was to assess the survival of women with  
 
advanced vulval cancer who were treated with primary chemoradiation. Our  
 
results are disappointing, both when looked at in isolation, and when  
 
compared with the results achieved at other institutions. For example, 
Thomas et al report complete response rates of 66% in patients receiving 
primary chemoradiation, and 53% in patients being treated for recurrent 
disease
8
. At Groote Schuur, the corresponding response rates are 28% and 
20% respectively. Long term survival is also poor in the Groote Schuur 
group, with only 15 (30%) patients living for longer than five years. This is 
similar to the 15 – 30% five year survival for stage 4 disease which is quoted 
by FIGO, and not nearly as good as their 50 - 75% five year survival for 
stage 3 disease. 
 
A sub-group analysis of the women who were alive and free of disease after  
 
five years shows that important prognostic factors for survival in advanced  
 
vulval cancer include good performance status, earlier tumour stage, and a 
 
complete response to chemoradiation when it is offered as the primary  
 
modality of treatment. Adjuvant surgery improves the survival of partial  
 













Possible reasons for the poor results produced at Groote Schuur, as  
 
compared to those of Thomas and others, include the very late presentation  
 
of those patients being treated at Groote Schuur. In the Groote Schuur group,  
 
the average diameter of the vulval lesions was 8,4cm, while the average size  
 
in the group treated by Thomas et al was 5,1cm. Women presenting at  
 
Groote Schuur did so only after symptoms had been present for an average  
 
of 7 months. Late presentation is characteristic of this disease, ot only due  
 
to possible lack of access to health care, but also because women are  
 
embarrassed and delay seeking help. 
 
The standard radiation dose given at GSH was 45Gy. This dose is probably 
inadequate, given the large average size of the tumours in this patient 
population. Thomas advises radiation doses of 55 to 65Gy in order to 
increase local control
8
. This advice is echoed by Koh et al, who found a 
correlation between radiation doses of greater than 50Gy, and overall local 
control
18
. They suggest that optimal radiation dose, when combined with 
chemotherapy, should be at least 54-55Gy
18
. Scheistroen and Trope, who 
also report disappointing results (25% complete response rate and 8 months 
median survival for patients with primary lesions), irradiated their patients 
with a maximum of 45Gy (30-45Gy), and conclude that increasing the 













8.3  Complications and morbidity of chemoradiation 
 
The obvious problem with increasing the radiation dose, is a corresponding  
 
increase in treatment morbidity, particularly skin and GIT complications.  
 
The thin, vascular vulval skin is known to tolerate radiation extremely  
 
poorly. A description of the complications and morbidity of chemoradiation  
 
was one of the objectives of our study. Studies reporting morbidity  
 
following treatment for vulval cancer are few and far between, and have  
 
only really been published in the last 20 years or so, coinciding with the  
 
increased emphasis on quality-of-life issues in cancer care. 
 
 
It stands to reason that the larger or more advanced the vulval tumour at  
 
presentation, the more modalities of treatment which may be required to  
 
achieve local control and cure, and therefore the greater the treatment-related  
 
morbidity can be expected to be. Radiotherapy has two phases of toxicity:  
 
acute toxicity, which occurs within three months of completion of treatment,  
 
and which is characterised by inflammation, and dry and moist  
 
desquamation; and delayed toxicity, which is characterised by scarring and  
 
fibrosis. When chemotherapy is used in combination with radiotherapy, this  
 
may lead to an increased rate of toxicity than radiation alone; and if this  
 
results in an increase in treatment interruptions, this may cause treatment to  
 











more likely to be intolerant of concomitant chemotherapy and radiotherapy,  
 





Many articles describe the skin desquamation that occurs during  
 
radiotherapy as ‘inevitable’, yet only 11 of the Groote Schuur patients are  
 
reported to have suffered from it. The fact that 29 of our patients had no  
 
acute complications of their treatment at all, lends support to the hypothesis  
 
that the doses of radiation given were possibly inadequate. We have no long- 
 
term follow-up data on more chronic complications such a lymphoedema,  
 
which is likely to be more of a problem in patients who have been treated  
 
with both radiotherapy and surgery.  
 
 
We also have no quality-of-life assessments, or assessments of  
 
psychological and psychosexual morbidity in our patients. Until recently,  
 
this has been a neglected area, though quality-of-life and psycho-sexual  
 
issues are gaining prominence in studies of the management of cancer. An  
 
early report on this subject found that more than 50% of women with vulval  
 
cancer and their partners experienced psychosexual problems. These are  
 
partly due to changes in anatomy, a lack of adequate counselling and advice  
 
















after treatment are increased age, poor performance status, a history of  
 
depression and pre-treatment psychosexual problems
37
. It is anticipated that  
 
the increased incidence of VIN and vulval cancer in younger women will  
 
lead to challenges in terms of the prevention and treatment of the 
 
psychosexual difficulties associated with vulval cancer therapies
35




8.4  The role of subsequent surgery 
 
Surgery was performed in 7 of the patients who had a partial response to  
 
chemoradiation. The results of the patients who had surgery are good: the  
 
mean survival time in that group is 85 months, with 3 of 5 patients (2 were  
 
lost to follow-up) surviving for longer than 5 years – a 60% 5 year survival.  
 
 
Although this small group makes up only 14% of the total, their results are  
 
so much better than those for the whole group, that they strongly suggest  
 
that surgery is an important part of the treatment regime if there is a partial  
 
response to chemoradiation. Koh’s findings are not as convincing: 7 patients  
 
in his series underwent surgery after a partial response to chemoradiation.  
 
Average survival time in this group was 22.7 months, with only 2 patients  
 
being free of disease at 3 years. None had survived longer than 37 months at  
 














Carcinoma of the vulva is traditionally quoted as being a disease of elderly 
women, and certainly in first world countries where there is a high incidence 
of lichen sclerosus and differentiated VIN, this is the case. These women 
tend to respond very poorly to chemoradiation, and have a high incidence of 
treatment related morbidity and mortality. However, this series shows that in 
populations where the prevalence of usual type VIN is high, the incidence of 
vulval carcinoma in younger women is rising, with the mean age of the 
women treated for advanced vulval carcinoma at GSH being only 54 years.  
 
Maximising long term survival in such a young group of women is  
 
obviously important, and it appears that surgery is a vital part of the  
 
treatment regime in order to achieve this. However, in the South African  
 
context, where the majority of women live in poor socio-economic  
 
conditions, often in informal settlements, where they may not have running  
 
water in their homes; and where a vast sector of the population is infected  
 
with HIV; extensive vulval surgery, particularly after radiotherapy to the  
 
vulva, with the prolonged hospitalization and lengthy healing process  
 
required, may be neither practical, nor appropriate.  
 
 
Fortunately, despite the high prevalence of HIV-related HPV disease,  
 












accuminata, vulval cancer remains extremely rare in South Africa. Advanced  
 




. The reasons for this are two-fold: firstly, until the recent  
 
widespread use of anti-retroviral therapy, women infected with HIV  
 
probably died of other causes before they had time to develop a vulval  
 
carcinoma; and secondly, usual type VIN is far less likely to undergo  
 
malignant change than differentiated VIN (Eva et al – personal  
 
communication and unpublished data).  
 
 
This is in contrast to HIV positive women with cervical intraepithelial  
 
neoplasia (CIN), who are known to be more likely to develop cervical  
 






8.5  The future: the roles of anti-retrovirals, HPV vaccines and  
 
          neoadjuvant chemotherapy 
  
As to what influence the role-out of highly active anti-retroviral therapy  
 
(HAART) in South Africa will have on the incidence of squamous  
 
carcinoma of the vulva, one might speculate that it may cause the incidence  
 
to increase, due to increased longevity of HIV-infected women. Anti- 
 
retrovirals have not been shown to be effective in reversing HPV-induced  
 















. Any effect is therefore likely to be indirect, following an 
 
improvement in host immune responses. 
 
 
It is estimated that about 40% of vulval cancers have a strong aetiological  
 




. Would HPV vaccines have an impact on the prevalence of vulval  
 
carcinoma? Two prophylactic HPV vaccines are now available: Gardasil™  
 
and Cervarix™. These are expected to play an important role in decreasing  
 
the incidence of HPV related disease worldwide, though in order to have a  
 
significant impact on disease burden, they must be available in developing  
 
countries. The high cost of the vaccines and competition for limited  
 
resources from other areas of  healthcare, as well as the logistics of  
 
delivering the vaccine in countries with poor infrastructure, and social  
 





Several studies have attempted to estimate the impact of the prophylactic  
 




assessed prevalence and types of HPV in order to estimate  
 












tract disease. They found that HPV DNA was detected in 92% of VIN  
 
samples and 60% of vulval carcinoma samples; and that high-risk HPV  
 







Women with HPV-positive samples were younger than those with HPV- 
 
negative samples (46 years compared with 55 years for VIN, and 51 years  
 
compared with 61 years for vulval cancer). Seventy-seven percent of vulval  
 
carcinomas in women less than 56 years were HPV-positive, whereas only  
 





They conclude that widely-implemented prophylactic HPV vaccination  
 
could prevent about two-thirds of VIN and about half of vulval  
 





Joura et al analysed the results of 3 trials which had randomised 18174  
 
women to receive either quadrivalent HPV6/11/16/18 L1 virus-like- 
 
particle vaccine or placebo. The mean follow-up time was 3 years. The  
 
vaccine was found to be 100% effective in preventing VIN or VaIN  
 
associated with HPV16 and HPV18 in women who were HPV16 and  
 
HPV18 naïve, and 71% effective in women who could have been infected  
 
















Garland et al have reported a randomised, placebo-controlled, double- 
 
blind trial involving 5455 women who had no virologic evidence of HPV  
 
6, 11, 16 or 18. 2723 women were assigned to receive a quadrivalent  
 
HPV vaccine, and 2732 to receive placebo, and were followed up for an  
 
average of three years. Vaccine efficacy was found to be 100% for each  
 
of the coprimary end points of incidence of genital warts, VIN and VaIN,  
 
or cancer, and the incidence of CIN, adenocarcinoma in situ, or cancer  
 
associated with HPV type 6, 11, 16, and 18. In addition, vaccination  
 
reduced the rate of any vulval or vaginal perianal lesions regardless of the  
 
causal HPV type by 34%, and the rate of cervical lesions regardless of the 
 





But vaccines are for the future prevention of HPV-related vulval cancers.  
 
Current trials of neoadjuvant chemotherapy, and other therapeutic agents  
 
such as the EGFR inhibitors, are possible alternatives to radiotherapy and  
 
chemoradiation in the management of advanced vulval carcinomas – used  
 
either as an adjunct to surgery, or on their own. 
 
 
The aims of therapy for advanced vulval cancers are to increase locoregional  
 











mortality. Though these tumours are rare, the management dilemmas and  
 
the treatment-associated morbidity they represent for each individual woman  
 
















































Chemoradiation has not been as successful a treatment for advanced vulval 
carcinoma at GSH, as was initially hoped. Considering that women who had 
a complete response to chemoradiation, and those who had surgery after a 
partial response to chemoradiation, had significantly improved survival, it is 
possible that our results could have been improved by increasing the 
radiation dose to a minimum of 55Gy, and by offering surgery to more of the 
partial responders; though both of these could also have increased the 
treatment-related morbidity and mortality suffered by the patients.  
 
The other factor which influenced the prognosis of our patients is the fact  
 
that they presented with extremely large tumours and advanced disease, and  
 
improvements in education and health-care provision in South Africa are  
 



























1) The prevention of vulval cancer by education of the general public  
 
and health care workers, and provision of an affordable HPV vaccine. 
 
2) The prevention of advanced cancers by education of both the general  
 
     public and health professionals, and increased access to health care.  
 
3) Funding for trials of the use of less toxic cytotoxic agents, such as  
 
carboplatin, as part of chemoradiation regimens and as neoadjuvant  
 
therapy (prior to surgery) for locally advanced vulval cancer. 
 
4) Funding for trials of the use of other drugs such as EGFR inhibitors -   
 
the results of ongoing trials are awaited. 
 
5) SURGERY: the recent Cochrane systematic review proclaims surgery   
 
to be the most important part of any treatment strategy, and this is  
 
supported by the results of this study. However, appropriateness of the  
 
use of widespread radical vulval surgery after radiotherapy in a  
 
developing world setting has yet to be evaluated. 
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12. APPENDIX 1  
 
VULVAL CHEMORADIATION PROFORMA 
 
1) Name      2)  Hospital number                                                                                
 
3)  Age at diagnosis (yrs)    4)  Gravidity    5)  Parity   6)  Race:  B W  C 
 
7) Origin: a) Cape Town   b) Eastern Cape   c) Rural Cape   d) Other 
 
8) Performance status (WHO):  
a) 0 = No symptoms 
     b) 1 = symptomatic but not bedridden 
          c) 2 = < 50% time in bed 
          d) 3 = >50% time in bed 
          e) 4 = bedridden 
 
9) Previous cancer: a) yes (              )  b) no  
 
10) Concurrent cancer: a) yes (            )  b) no 
 
11) Associated vulval conditions:  
      a) nil  b) LS  c) VIN  d) Paget’s  e) Vulval warts 
 
12) Immunosuppression:  
 a) HIV   b) Renal transplant   c) Steroids    d) nil 
 
13) Pap smear result:  
      a) inadequate b) benign c) ASCUS d) LSIL e) HSIL f) AGUS 
           g) malignant h) nil 
 
14) Histology: a) squamous cell ca  b) other 
 
15) FIGO stage at diagnosis:  
      a) 1A   b) 1B   c) 2    d) 3    e) 4A     f) 4B   g)unknown 
 
16) TNM classification:  













17) Size of tumour (cm):  
a) < = 1      b) 1,1 – 2   c) 2,1 – 3   d) 3,1 – 4   e) 4,1 – 5                                  
f) 5,1 – 6    g) 6,1 – 7   h) 7,1 – 8   i) 8,1 – 9                                             
j) 9,1 – 10   k) > 10 
 
18) Site of tumour:  
 a) central anterior 
 b) central posterior 
           c) labia minora 
           d) labia majora 
 
19) Sites of extension of disease:  
      a) vagina  b) anus  c) rectum  d) urethra  e) bladder                                                      
      f)  bone     g) nil 
 
20) Groin nodes:  
       a) clinically negative 
       b) unilaterally clinically positive \ not FNAB-proven 
       c) bilateral clinically positive \ not FNAB-proven 
       d) unilateral FNAB-positive 
            e) bilateral FNAB-positive 





21) Chemotherapy:  
 a) MFU 1 cycle   b) MFU 2 cycles 
 
22) Radiotherapy:  
     a) 1 split course  b) 2 split courses c) continuous  d) RT boosts 
 
23) Treatment completed:  
      a) yes   
      b) no -  Why? - Complications – absconded – died 
 
24) Complications:  
      a) wet desquamation skin  b) haematologic  c) uncontrollable emesis 












25) Response to chemoradiation:  
      a) complete response (CR) 
      b) partial response (PR) 
      c) no change (NC) 
           d) progressive disease (PD) 





26) Surgery performed:  
      a)yes   b) no 
 
27) Type of surgery:  
      a) local excision  b) simple vulvectomy  c) radical vulvectomy 
      d) other 
 
28) Node dissection:  
      a) unilateral   b) bilateral    c) not performed 
 
29) Residual disease:    
      a) yes   b) no 
           If yes – completely excised 
                     -  incompletely excised ( + margins) 
 
     30) Further treatment:  
           a) none   b) radiotherapy   c) surgery   d) chemotherapy 
 
      
     OUTCOME 
 
     31) Follow-up from 1
st 
 treatment (months): 
 
     32) Recurrence:  
   a) yes   b) no   
           If yes – local,  groin,  distant,  local + groin,  local + distant,  
           local + groin + distant 
 
      











33) Current status:  
           a) alive – no disease 
           b) alive – disease 
           c) dead – cancer 
           d) dead – other causes 
           e) dead – treatment complications 
           f) lost to follow-up 
 




     35) Disease-free survival:    
       
 
 
 
 
 
 
 
 
 
 
 
 
 
